短腸症候群(SBS)治療の世界市場

◆英語タイトル:Global Short Bowel Syndrome (SBS) Market 2017-2021
◆商品コード:IRTNTR12927
◆発行会社(リサーチ会社):Technavio
◆発行日:2017年5月31日
◆ページ数:70
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、短腸症候群(SBS)治療の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、短腸症候群(SBS)治療の世界市場規模及び予測、投与経路(ROA)別分析、薬剤種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

・エグゼクティブサマリー
・短腸症候群(SBS)治療の世界市場:市場概観
・短腸症候群(SBS)治療の世界市場:業界の構造分析
・短腸症候群(SBS)治療の世界市場:市場規模及び予測
・短腸症候群(SBS)治療の世界市場:投与経路(ROA)別分析
・短腸症候群(SBS)治療の世界市場:薬剤種類別分析
・短腸症候群(SBS)治療の世界市場:地域別分析
・短腸症候群(SBS)治療の世界市場:アジア市場規模
・短腸症候群(SBS)治療の世界市場:アメリカ市場規模
・短腸症候群(SBS)治療の世界市場:ヨーロッパ市場規模
・短腸症候群(SBS)治療の世界市場:成長要因
・短腸症候群(SBS)治療の世界市場:課題
・短腸症候群(SBS)治療の世界市場:市場動向
・短腸症候群(SBS)治療の世界市場:競争状況
・短腸症候群(SBS)治療の世界市場:主要企業(ベンダー)分析
...

※上記の和訳は最新内容ではない場合があります。
【レポートの概要】

About Short Bowel Syndrome (SBS)Short bowel syndrome (SBS) is a metabolic disorder occurs when the portion of the small intestine is not functioning or removed through surgery due to digestive illness. SBS is caused by lack of function of the small intestine. This results in malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition. Based on drug class, the market is segmented into GLP-2, growth hormone, glutamine, and others.

Technavio’s analysts forecast the global short bowel syndrome (SBS) market to grow at a CAGR of 25.53% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global short bowel syndrome (SBS) market for 2017-2021. To calculate the market size, the report considers the sales of the drugs and related nutraceutical products.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Short Bowel Syndrome (SBS) Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Emmaus Medical
• Merck
• Shire

[Other prominent vendors]
• Ardelyx
• Naia Pharmaceuticals
• Nutrinia
• OxThera
• Sancilio Pharmaceuticals
• Zealand Pharma

[Market driver]
• Special drug designations
• For a full, detailed list, view our report

[Market challenge]
• Severe side effects of the drugs
• For a full, detailed list, view our report

[Market trend]
• Increased awareness of GI disorders
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline
• Diagnosis and testing

PART 05: Orphan drug designation

PART 06: Pipeline landscape

PART 07: Market landscape
• Market overview
• Five forces analysis

PART 08: Market segmentation by route of administration (ROA)
• Oral
• Parenteral

PART 09: Market segmentation by drug class
• GLP-2
• Growth hormone
• Glutamine
• Others

PART 10: Geographical segmentation
• SBS market in Americas
• SBS in EMEA
• SBS market in APAC

PART 11: Decision framework

PART 12: Drivers and challenges
• Market drivers
• Market challenges

PART 13: Market trends
• Increased awareness of GI disorders
• Emerging markets
• Focus on gene therapy

PART 14: Vendor landscape
• Competitive scenario

PART 15: Key vendor analysis
• Emmaus Medical
• Merck
• Shire
• Other prominent vendors

PART 16: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Parts of small intestine
Exhibit 02: Causes of SBS
Exhibit 03: Key SBS drugs
Exhibit 04: Diagnostic test for SBS
Exhibit 05: Incentives of orphan drug designation
Exhibit 06: Orphan drugs approved for SBS
Exhibit 07: Overview of case study I
Exhibit 08: Overview of case study II
Exhibit 09: Overview of case study III
Exhibit 10: Global SBS market: Pipeline landscape
Exhibit 11: Global SBS market overview
Exhibit 12: Global SBS market 2016-2021 ($ millions)
Exhibit 13: Opportunity analysis in global SBS market
Exhibit 14: Five forces analysis
Exhibit 15: Segmentation of global SBS market by ROA 2016
Exhibit 16: Market share of global SBS market by ROA 2016 (%)
Exhibit 17: Segmentation of global SBS market by drug class 2016
Exhibit 18: Market share of global SBS market by drug class 2016 (%)
Exhibit 19: Global GLP-2 drugs market 2016-2021 ($ millions)
Exhibit 20: Global SBS human growth hormone market 2016-2021 ($ millions)
Exhibit 21: Global SBS glutamine market 2016-2021 ($ millions)
Exhibit 22: Segmentation of SBS market based on geography 2016 and 2021
Exhibit 23: Global SBS market revenue by geography 2016-2021 ($ millions)
Exhibit 24: Market scenario in Americas
Exhibit 25: SBS market in Americas 2016-2021 ($ millions)
Exhibit 26: Market scenario of EMEA
Exhibit 27: SBS market in EMEA 2016-2021 ($ millions)
Exhibit 28: Market scenario of APAC
Exhibit 29: SBS market in APAC 2016-2021 ($ millions)
Exhibit 30: Key approvals for different regions
Exhibit 31: Competitive structure analysis of global SBS market 2016
Exhibit 32: Strategic success factors of companies in global SBS market
Exhibit 33: Emmaus Medical: Strength assessment
Exhibit 34: Emmaus Medical: Strategy assessment
Exhibit 35: Emmaus Medical: Opportunity assessment
Exhibit 36: Merck: Strength assessment
Exhibit 37: Merck: Strategy assessment
Exhibit 38: Merck: Opportunity assessment
Exhibit 39: Shire: Key highlights
Exhibit 40: Shire: Strength assessment
Exhibit 41: Shire: Strategy assessment
Exhibit 42: Shire: Opportunity assessment



【掲載企業】

Emmaus Medical, Merck, Shire, Ardelyx, Naia Pharmaceuticals, Nutrinia, OxThera, Sancilio Pharmaceuticals, and Zealand Pharma.

【レポートのキーワード】

短腸症候群(SBS)、短腸症候群治療薬、医薬品

【リサーチ方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[短腸症候群(SBS)治療の世界市場]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチのお客様(例)◆